← Eichor
Study identifier: NCT07530770 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis

Condition: Allergic Bronchopulmonary Aspergillosis · Severe Asthma · ABPA  ·  Sponsor: Qianfoshan Hospital

PhaseN/A
Planned participants20
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis

This description comes directly from the study's public registry record.

Talk to the study team

Qian Qi, Dr.  ·  +86 13706380314  ·  qiqianqlh@163.com

Always discuss trial participation with your own doctor first.

Locations (2)

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, ChinaJinan, Shandong, ChinaRecruiting
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical UniversityJinan, Shandong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07530770